SOURCE: Velcera, Inc.

November 05, 2007 06:00 ET

Velcera to Present at 9th Annual Acumen BioFin Healthcare Conference

YARDLEY, PA--(Marketwire - November 5, 2007) - Velcera, Inc. (OTCBB: VLCR), a specialty pharmaceutical company focused on pet health, announced today that it will be presenting at the 9th Annual Acumen BioFin Healthcare Conference to be held November 5-7, 2007 at the New York Palace Hotel. The Company's President and CEO, Dennis Steadman, will present an overview of the company and ongoing development programs based on its novel Promist™ drug delivery system. Mr. Steadman will be presenting on Tuesday, November 6 at 5:05 p.m. (ET) in the Holmes II room (4th floor). For more information on this event please visit: http://www.rodmanandrenshaw.com/conferences.

To participate in a live audio webcast of Mr. Steadman's presentation please log onto http://www.wsw.com/webcast/rrshq12/velcera at least fifteen minutes prior to the start of the presentation to download any necessary materials. An archive of this event will be available in the investor relations section of the Velcera website (www.velcera.com) for 90 days.

About Velcera, Inc.

Velcera (OTCBB: VLCR) is a specialty pharmaceutical company focused on leveraging its patented Promist™ delivery system to develop veterinary medicines with superior convenience, compliance, and pharmacokinetic advantages that benefit pets and their owners. Promist delivery provides a metered dose liquid mist to the oral mucosa for systemic absorption. The convenience of Promist has the potential to increase compliance and improve pet health as owners avoid the challenge of getting pets to swallow pills. Other advantages of Promist include improved bioavailability, faster absorption and avoidance of the GI track.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that could cause our actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Risks that may affect forward-looking information contained in this press release include, without limitation, the risk that the results of clinical trials may not support our claims and our lack of experience in developing and commercializing pet pharmaceutical products. Additional risks are described in our Current Report on Form SB-2/A filed with the Securities and Exchange Commission on October 18, 2007 We assume no obligation to update these statements, except as required by law.

Contact Information

  • For more information, please contact:

    Velcera, Inc.
    Dennis Steadman
    President and CEO
    Phone: 267-757-3600
    Fax: 267-757-3601
    Email Contact

    The Ruth Group
    Sara Ephraim (investors)
    Phone: 646-536-7002
    Email Contact

    Jason Rando (media)
    Phone: 646-536-7025
    Email Contact